Manufacturing CAR-NK against tumors: Who is the ideal supplier?
Chin J Cancer Res
; 36(1): 1-16, 2024 Feb 29.
Article
en En
| MEDLINE
| ID: mdl-38455373
ABSTRACT
Chimeric antigen receptor-natural killer (CAR-NK) cells have emerged as another prominent player in the realm of tumor immunotherapy following CAR-T cells. The unique features of CAR-NK cells make it possible to compensate for deficiencies in CAR-T therapy, such as the complexity of the manufacturing process, clinical adverse events, and solid tumor challenges. To date, CAR-NK products from different allogeneic sources have exhibited remarkable anti-tumor effects on preclinical studies and have gradually been applied in clinical practice. However, each source has advantages and disadvantages. Selecting a suitable source may help maximize CAR-NK cell efficacy and increase the feasibility of clinical transformation. Therefore, this review discusses the development and challenges of CAR-NK cells from different sources to provide a reference for future exploration.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Idioma:
En
Revista:
Chin J Cancer Res
Año:
2024
Tipo del documento:
Article
País de afiliación:
China
Pais de publicación:
China